BioWorld

April 30, 2008

Second Strike on Rituxan as it Fails in Lupus Trial

Still reeling from a negative study of Rituxan in multiple sclerosis patients, Genentech Inc. and Biogen Idec Inc. reported more unfavorable data Tuesday from a Phase II/III study of the drug in lupus patients. (BioWorld Today) Read More

Constellation's Series A Adds $32M for Epigenetics Platform

Paper Stirs Science Debate Over Tumor Angiogenesis

Panel Debates Knotty Challenges Facing Follow-on Biologics

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...